A Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of V24343 on Blood Pressure and Weight in Obese Subjects
Latest Information Update: 28 Jul 2011
At a glance
- Drugs Selonabant (Primary)
- Indications Obesity
- Focus Adverse reactions
- 22 Jul 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2009 Planned end date changed from 1 Jan 2009 to 1 Mar 2009 as reported by ClinicalTrials.gov.